ODT News and Press, Odonate Therapeutics Inc. From 11/06/19

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and nine months ended September 30, 2019. As of Septem...

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the completion of enrollment in CONTESSA, a multinational, multicenter, randomized, Phase ...

We already know that this is a crazy financial world we live in: Global Manufacturing is Crashing Investors Run to Safety Monetary Policy Made a Sharp U-Turn Bonds Have Gone Mad Recession Seems More and More Likely In such a world, it's no wonder t...

Listen and subscribe to the Marketplace Roundtable on these podcast platforms: iTunes/Apple Podcasts Spotify Stitcher By Nathaniel E. Baker Dr. Ashok Dutta of Avisol Capital Partners joins the Marketplace Roundtable podcast to discuss his approach to in...

Odonate Therapeutics (NASDAQ: ODT ): Q2 GAAP EPS of -$1.15 beats by $0.05 . More news on: Odonate Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and six months ended June 30, 2019. As of June 30, 201...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

Odonate Therapeutics ( ODT ) is led by Kevin Tang, a successful serial biopharma entrepreneur who has made billions in the industry, most notably from the sale of Ardea Biosciences, which he founded, to AstraZeneca (AZN) for $1bn. Mr. Tang owns over 50% of Odonate. ODT focuses on a single drug...

Odonate Therapeutics ( ODT -0.3% ) prices its public offering of 4.75M shares at $26/share, and expects gross proceeds of ~$123.5M More news on: Odonate Therapeutics, Inc., Healthcare stocks news, Read more ...

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the pricing of an underwritten public offering of 4,750,000 shares of its common stock, offe...